Guided Therapeutics

GTHP

Medical - Devices · Healthcare

Price

$0.28

+0.00 (+0.00%)

Market Cap

$21.5M

Winston Score

–

No score yet — Winston is napping.

We couldn’t gather enough financial data to score this stock reliably.

Share count rising — dilution

+486.2% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 13.4M (2021) → 78.4M (2025)

Guided Therapeutics is a small medical device company that makes a tool to help doctors detect cervical cancer earlier. Its main product is the LuViva Advanced Cervical Scan, a non-invasive device that uses light to check cervical tissue without needing a biopsy or lab test. The company sells to healthcare providers and targets markets where cervical cancer screening is limited or underserved.

The company earns revenue by selling its scanning devices and related disposable components used during each exam. It operates primarily in international markets, including parts of Asia and the Middle East, where regulatory approvals have been easier to obtain than in the United States. Guided Therapeutics is a very small company with a market cap near zero, and its deep operating losses show it spends far more than it earns. The biggest risk is whether it can secure enough funding and regulatory clearances to scale sales before running out of cash.

Winston Score History

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

>+1,000% YoY

YoY Growth Rate

Revenue accelerating

EPS Growth

-3.3% YoY

YoY Growth Rate

Earnings declining

R&D Spend

$469,000/ year

↓ Declining (-11% vs prior year)

61.1% of revenue

3.4x the sector average (18%)

R&D spend declining — could signal cost-cutting or efficiency

Insider Activity

59.2%ownership

→ Flat

Insiders holding steady — not selling despite ability to

Cash Runway

~1 months

$63,000 cash & investments

Short runway — potential dilution ahead through share issuance

Revenue accelerating

Guided Therapeutics grew revenue 58900% year-over-year and the growth rate is speeding up. That's the kind of momentum growth investors look for — the question is whether margins can follow.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin

77.6%

Premium pricing power — 77.6% gross margin

Operating Margin

-120.3%

Losing money on operations — -120.3%

ROCE

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY

+10857.1%

Fast-growing sales (10857.1% YoY)

EPS YoY

N/A

—

Data not available

EPS Consistency

0/8 quarters

Earnings rarely grow — volatile business

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion

N/A

—

Data not available

FCF Margin

-139.5%

Burning cash (-139.5%)

Free cash flow is negative. They are burning cash, not generating it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity

N/A

Data not available

Interest Cover

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio (TTM)

N/M

—

Negative earnings — P/E not meaningful

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial